TORIPALIMAB for Malignant melanoma: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 36 adverse event reports in the FDA FAERS database where TORIPALIMAB was used for Malignant melanoma.
Most Reported Side Effects for TORIPALIMAB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Myelosuppression | 590 | 43.9% | 3 | 432 |
| Off label use | 276 | 20.5% | 29 | 137 |
| White blood cell count decreased | 144 | 10.7% | 0 | 74 |
| Anaemia | 67 | 5.0% | 17 | 8 |
| Hypothyroidism | 67 | 5.0% | 13 | 11 |
| Neutrophil count decreased | 67 | 5.0% | 0 | 25 |
| Nausea | 60 | 4.5% | 7 | 14 |
| Rash | 59 | 4.4% | 7 | 11 |
| Vomiting | 58 | 4.3% | 7 | 14 |
| Platelet count decreased | 53 | 3.9% | 3 | 30 |
| Diarrhoea | 50 | 3.7% | 6 | 16 |
| Neutropenia | 49 | 3.7% | 8 | 1 |
| Thrombocytopenia | 48 | 3.6% | 12 | 0 |
| Pyrexia | 46 | 3.4% | 2 | 13 |
| Decreased appetite | 43 | 3.2% | 9 | 9 |
Other Indications for TORIPALIMAB
Nasopharyngeal cancer (163)
Hepatocellular carcinoma (125)
Oesophageal carcinoma (72)
Lung neoplasm malignant (65)
Breast cancer (40)
Small cell lung cancer (36)
Hepatic cancer (34)
Renal cancer (34)
Bladder cancer (33)
Oesophageal squamous cell carcinoma stage iv (29)
Other Drugs Used for Malignant melanoma
NIVOLUMAB (10,599)
IPILIMUMAB (8,903)
DABRAFENIB (5,277)
TRAMETINIB DIMETHYL SULFOXIDE (3,841)
PEMBROLIZUMAB (3,261)
BINIMETINIB (2,613)
ENCORAFENIB (2,591)
VEMURAFENIB (2,548)
TRAMETINIB (1,448)
COBIMETINIB (1,324)